Condition
Sickle Cell Anaemia
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Not Yet Recruiting3
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06743113Not ApplicableNot Yet RecruitingPrimary
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT07282210Phase 2Not Yet Recruiting
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
NCT06601894Not Yet RecruitingPrimary
The Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia
NCT02844673Phase 2CompletedPrimary
Mobile-Directly Observed Therapy on Adherence to Hydroxyurea
NCT00415727Phase 2UnknownPrimary
Prevention Of Morbidity In Sickle Cell Disease Pilot Phase
Showing all 5 trials